Literature DB >> 12969869

Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.

Claudia L Ordoñez1, Noreen R Henig, Nicole Mayer-Hamblett, Frank J Accurso, Jane L Burns, James F Chmiel, Cori L Daines, Ronald L Gibson, Sharon McNamara, George Z Retsch-Bogart, Pamela L Zeitlin, Moira L Aitken.   

Abstract

Induced sputum has been used to study airway inflammation. We sought to determine whether markers of infection and inflammation in induced sputum were a useful and safe outcome measure in cystic fibrosis. We hypothesized that bacterial density and inflammatory content of induced sputum would decrease after antibiotic therapy. Induced sputum was assayed for bacterial density, cell count, and differential and inflammatory markers before and after treatment with intravenous antibiotics. Fifty-five of the 72 subjects enrolled (mean age +/- SD 18.2 +/- 7.9 years) completed the study. FEV1 increased by an average 0.3 +/- 0.3 L (10.4 +/- 8.7% predicted FEV1), p<0.0001; density of Pseudomonas aeruginosa and Staphylococcus aureus decreased by 2.4 +/- 3.1 log10 cfu/g (p<0.0005) and 4.0 +/- 2.3 log10 cfu/ml (p<0.0001), respectively; neutrophil count decreased by 0.4 +/- 0.6 log10 cells/ml (p<0.0001), interleukin-8 concentration by 0.5 +/- 1.3 log10 pg/ml (p<0.05), and neutrophil elastase by 0.4 +/- 0.7 log10 microg/ml (p<0.005). Seven of 127 (6%) sputum induction procedures showed a decrease in FEV1 of 20% or more. We conclude that markers in induced sputum may be useful, noninvasive outcome measures to assess response to therapies in cystic fibrosis studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969869     DOI: 10.1164/rccm.200306-731OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  59 in total

1.  Pediatric Respiratory Assembly. Mini symposium on lung inflammation.

Authors:  Larry C Lands; A Keith Tanswell; Sophie Laberge; Christine McCusker; Felix Ratjen
Journal:  Can Respir J       Date:  2010 Mar-Apr       Impact factor: 2.409

Review 2.  Building global development strategies for cf therapeutics during a transitional cftr modulator era.

Authors:  N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart
Journal:  J Cyst Fibros       Date:  2020-06-07       Impact factor: 5.482

Review 3.  New insights into pulmonary inflammation in cystic fibrosis.

Authors:  S Rao; J Grigg
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

4.  Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.

Authors:  Theresa A Laguna; Brandie D Wagner; Heidi K Luckey; Shelley A Mann; Scott D Sagel; Warren Regelmann; Frank J Accurso
Journal:  Chest       Date:  2009-06-30       Impact factor: 9.410

5.  Sputum induction improves detection of pathogens in children with cystic fibrosis.

Authors:  Jordana E Hoppe; Elinor Towler; Brandie D Wagner; Frank J Accurso; Scott D Sagel; Edith T Zemanick
Journal:  Pediatr Pulmonol       Date:  2015-01-07

Review 6.  Emerging Roles of Carbonyl Sulfide in Chemical Biology: Sulfide Transporter or Gasotransmitter?

Authors:  Andrea K Steiger; Yu Zhao; Michael D Pluth
Journal:  Antioxid Redox Signal       Date:  2017-05-18       Impact factor: 8.401

7.  Lung transplantation for cystic fibrosis.

Authors:  Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou
Journal:  Proc Am Thorac Soc       Date:  2009-12

Review 8.  Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.

Authors:  N Mayer-Hamblett; D R VanDevanter
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

9.  Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung.

Authors:  Rishi Pabary; Charanjit Singh; Sandra Morales; Andrew Bush; Khalid Alshafi; Diana Bilton; Eric W F W Alton; Anthony Smithyman; Jane C Davies
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

10.  In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients.

Authors:  Andreas Hector; Matthias Kappler; Matthias Griese
Journal:  Mediators Inflamm       Date:  2010-06-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.